GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 5,358 | 7,286 | 8,968 | 9,682 | 39,505 |
| Marketable Securities | 18,367 | 19,454 | 23,011 | 26,031 | N/A |
| TOTAL | $23,947 | $27,193 | $32,169 | $35,798 | $39,567 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 223 | 246 | 0 | 0 | 0 |
| TOTAL | $223 | $246 | $N/A | $N/A | $N/A |
| Total Assets | $24,170 | $27,439 | $32,169 | $35,798 | $39,567 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 7,263 | 8,113 | 8,189 | 2,802 | 1,497 |
| Accrued Expenses | 1,129 | 1,170 | 1,901 | 749 | 906 |
| Other current liabilities | 115 | 120 | 138 | 340 | 842 |
| TOTAL | $8,610 | $9,503 | $10,259 | $3,922 | $3,276 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 120 | 147 | 0 | 0 | 0 |
| TOTAL | $120 | $147 | $N/A | $N/A | $N/A |
| Total Liabilities | $8,730 | $9,650 | $10,259 | $3,922 | $3,276 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,035 | 1,016 | 1,070 | 1,018 | 1,015 |
| Common Shares | 31 | 32 | 1,145 | 3,446 | 10,744 |
| Retained earnings | -662,003 | -659,024 | -653,584 | -635,393 | -629,940 |
| Other shareholders' equity | 1 | 1 | 1 | -168 | -168 |
| TOTAL | $15,440 | $17,789 | $21,910 | $31,876 | $36,291 |
| Total Liabilities And Equity | $24,170 | $27,439 | $32,169 | $35,798 | $39,567 |